CYP2B23 Inhibitors
CYP2B23 inhibitors are a distinct class of chemical compounds designed to specifically target and inhibit the activity of the CYP2B23 enzyme, a member of the cytochrome P450 superfamily. CYP2B23 is involved in the oxidative metabolism of a wide range of substrates, including both endogenous compounds such as hormones, fatty acids, and signaling molecules, and exogenous substances like drugs and environmental chemicals. The enzyme functions by catalyzing the monooxygenation of these substrates, a process that involves the incorporation of an oxygen atom into the substrate, typically making it more polar and facilitating its further metabolism or excretion. This oxidative modification is a crucial step in the biotransformation and detoxification pathways that maintain cellular homeostasis and protect the organism from potentially harmful compounds.
Inhibitors of CYP2B23 are typically small molecules designed to interact with the enzyme's active site, effectively blocking its catalytic activity. These inhibitors may function by binding to the substrate-binding pocket, thus preventing the natural substrates from accessing the catalytic core, or by inducing conformational changes that reduce the enzyme's efficiency in catalyzing oxidative reactions. The development of CYP2B23 inhibitors requires a detailed understanding of the enzyme's structure, particularly the regions involved in substrate recognition and catalytic activity. By inhibiting CYP2B23, researchers can investigate the specific role of this enzyme in various metabolic pathways, particularly how it influences the metabolism of different compounds within the broader network of cytochrome P450 enzymes. The study of CYP2B23 inhibitors provides valuable insights into the enzyme's substrate specificity, its interaction with other metabolic enzymes, and its overall contribution to the maintenance of metabolic balance in the body. This research enhances our understanding of the complex functions of cytochrome P450 enzymes and their critical roles in the biotransformation of a wide array of chemical entities within biological systems.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Fluconazole | 86386-73-4 | sc-205698 sc-205698A | 500 mg 1 g | $54.00 $84.00 | 14 | |
Fluconazole, a direct inhibitor of CYP2B23, disrupts its heme binding and monooxygenase activities. This interference extends to xenobiotic catabolic processes, suggesting a role in cellular detoxification mechanisms and response modulation. | ||||||
Ketoconazole | 65277-42-1 | sc-200496 sc-200496A | 50 mg 500 mg | $63.00 $265.00 | 21 | |
Ketoconazole directly inhibits CYP2B23, influencing its heme binding and monooxygenase activities. This modulation extends to steroid metabolic processes, suggesting a potential role in regulating steroid biosynthesis. | ||||||
Efavirenz | 154598-52-4 | sc-207612 | 10 mg | $171.00 | 3 | |
Efavirenz, a direct inhibitor of CYP2B23, impacts its heme binding and monooxygenase activities. This interference extends to xenobiotic catabolic processes, suggesting a potential role in cellular detoxification mechanisms and response regulation. | ||||||
Miconazole | 22916-47-8 | sc-204806 sc-204806A | 1 g 5 g | $66.00 $160.00 | 2 | |
Miconazole, as a direct inhibitor of CYP2B23, disrupts its heme binding and monooxygenase activities. This interference extends to xenobiotic catabolic processes, suggesting a role in cellular detoxification mechanisms and response modulation. | ||||||
Clarithromycin | 81103-11-9 | sc-205634 sc-205634A | 100 mg 250 mg | $77.00 $122.00 | 1 | |
Clarithromycin serves as a direct inhibitor of CYP2B23, influencing its heme binding and monooxygenase activities. This modulation extends to xenobiotic catabolic processes, suggesting a potential role in cellular detoxification mechanisms and response regulation. | ||||||
Ritonavir | 155213-67-5 | sc-208310 | 10 mg | $124.00 | 7 | |
Ritonavir acts as a direct inhibitor of CYP2B23, impacting its heme binding and monooxygenase activities. This interference extends to xenobiotic catabolic processes, suggesting a potential role in cellular detoxification mechanisms and response modulation. | ||||||
FK-506 | 104987-11-3 | sc-24649 sc-24649A | 5 mg 10 mg | $78.00 $151.00 | 9 | |
FK-506 inhibits CYP2B23 directly, influencing its heme binding and monooxygenase activities. This interference extends to xenobiotic catabolic processes, suggesting a potential role in cellular detoxification mechanisms and response modulation. | ||||||
Terbinafine | 91161-71-6 | sc-338609 | 100 mg | $560.00 | 1 | |
Terbinafine, a direct inhibitor of CYP2B23, disrupts its heme binding and monooxygenase activities. This interference extends to xenobiotic catabolic processes, suggesting a role in cellular detoxification mechanisms and response modulation. | ||||||
Fluoxetine | 54910-89-3 | sc-279166 | 500 mg | $318.00 | 9 | |
Fluoxetine serves as a direct inhibitor of CYP2B23, influencing its heme binding and monooxygenase activities. This modulation extends to xenobiotic catabolic processes, suggesting a potential role in cellular detoxification mechanisms and response regulation. | ||||||
Disulfiram | 97-77-8 | sc-205654 sc-205654A | 50 g 100 g | $53.00 $89.00 | 7 | |
Disulfiram acts as a direct inhibitor of CYP2B23, interfering with its heme binding and monooxygenase activities. This modulation extends to xenobiotic catabolic processes, suggesting a role in cellular detoxification mechanisms and response modulation. | ||||||